City Therapeutics, Inc. Common Stock Asset Resilience Ratio
City Therapeutics, Inc. Common Stock asset resilience ratio. City Therapeutics, Inc. Common Stock (CTY) has an Asset Resilience Ratio of 15.16% as of June 2010. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CTY defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of City Therapeutics, Inc. Common Stock (2006–2007)
Asset resilience ratio of City Therapeutics, Inc. Common Stock from 2006 to 2007. This chart shows how City Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read how much debt does City Therapeutics, Inc. Common Stock carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down City Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CTY total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $138.00 Million | 15.16% |
| Total Liquid Assets | $138.00 Million | 15.16% |
Asset Resilience Insights
- Good Liquidity Position: City Therapeutics, Inc. Common Stock maintains a healthy 15.16% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
City Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare City Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 10.35% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
LegoChem Biosciences Inc
KQ:141080 |
Biotechnology | 55.88% |
|
DNA Link Inc
KQ:127120 |
Biotechnology | 0.00% |
City Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2006–2007)
City Therapeutics, Inc. Common Stock asset resilience ratio by year from 2006 to 2007. The table below shows the annual Asset Resilience Ratio data for City Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2007-12-31 | 2.86% | $20.00 Million | $700.00 Million | +2.57pp |
| 2006-12-31 | 0.28% | $42.00 Million | $14.85 Billion | -- |
About City Therapeutics, Inc. Common Stock
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more